Damaged muscles in ALS patients release proteins previously linked only to brain disease In a nutshell Researchers discovered ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) is set to participate in the 13th Alzheimer’s & Parkinson’s Drug Development ...

Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

Amlenetug is tailored to attach to all major extracellular α-synuclein forms. The human monoclonal antibody aims to prevent ...

Researchers found that peristaltic pump flow mechanically breaks supersaturation to induce amyloid formation by hen egg white lysozyme, a-synuclein, amyloid b 1-40, and b2-microglobulin. The high ...

LBD occurs due to unusual brain deposits of a protein known as alpha-synuclein. Experts call these protein deposits Lewy bodies. In an unaffected brain, alpha-synuclein plays an important role ...

The new research reveals how a protein in brain cells may drive Parkinson's onset -- and offers a possible explanation for why Parkinson's is much more common in men.

Aging significantly impacts neurodegeneration, increasing risks for diseases like Alzheimer's. Research focuses on therapies to enhance cognitive function.

The 13th Alzheimer’s & Parkinson’s Drug Development Summit is the only industry-focused, end-to-end meeting that provides comprehensive coverage from early discovery to late-stage development focused ...

A new study reveals that T cells mistakenly attack brain cells expressing PINK1, contributing to Parkinson’s disease. The research also highlights a striking sex difference, with men showing a sixfold ...

A new study supports a link between obstructive sleep apnea and increased risk for Parkinson’s disease and suggests early use ...